4D Molecular Therapeutics, Inc. (NasdaqGS: FDMT)
Health Care · Biotechnology · US
$13.33
+4.96% today · +39.4% 1Y
4D Molecular Therapeutics, Inc. (NasdaqGS: FDMT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $736.41M and employs 196 people.
Over the last twelve months the share price has gained 39.4%, trading between 6.96 and 16.93.
Tweenvest scores 4D Molecular Therapeutics, Inc. across four factors: quality 38/100, value 60/100, growth 100/100. Its strongest factor is growth.
FDMT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $736.41M
- Revenue (TTM)
- $92.01M
- P/E
- —
- EPS
- -2.77
- Dividend yield
- —
- Beta (5Y)
- 2.74
- 52-week high
- $16.93
- 52-week low
- $6.96
- Avg volume (3M)
- —
- Shares outstanding
- 55.24M
- Employees
- 196
- Next earnings
- —
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
- ISIN
- US35104E1001
- Founded
- 2013
- Listed since
- Dec 11, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Gyre Therapeutics, Inc.NasdaqCM: GYRE | $746.48M | $7.04 | -0.98% |
| JS Link, Inc.KOSDAQ: A127120 | $743.20M | ₩28,750.00 | -1.54% |
| HanchorBio Inc.TWSE: 7827 | $739.81M | NT$169.00 | +1.20% |
| Solid Biosciences Inc.NasdaqGS: SLDB | $736.64M | $6.87 | +0.29% |
| Avalo Therapeutics, Inc.NasdaqCM: AVTX | $732.05M | $13.65 | +1.64% |
| Design Therapeutics, Inc.NasdaqGS: DSGN | $729.08M | $11.65 | +1.39% |
| ChemPartner PharmaTech Co.,Ltd.SZSE: 300149 | $713.97M | CN¥9.47 | -4.34% |
| Prime Medicine, Inc.NasdaqGM: PRME | $709.84M | $3.99 | +11.45% |
Figures last refreshed Oct 11, 2026.